Literature DB >> 12145728

Recent advances in the treatment of Acanthamoeba keratitis.

Raman Kumar1, David Lloyd.   

Abstract

Infection of the eye caused by Acanthamoeba species constitutes a burgeoning and unsolved problem. Of individuals with Acanthamoeba keratitis, 85% wear contact lenses; abrasion of the cornea is implicated. Corneal infection often can be prevented by good lens care and hygiene. Severe Acanthamoeba keratitis often can be very difficult to treat; surgery can be less than successful and may lead to further problems. The encysted stage in the life cycle of Acanthamoeba species appears to cause the most problems; many biocides are ineffective in killing the highly resistant cysts. Combination therapy--that is, use of 2 or 3 biocides, sometimes with antibacterial antibiotics--appears to work best. Recurrence is common if treatment is stopped prematurely. Immunologic methods are being investigated as a form of prevention, and oral immunization of animals recently has been successful in the prevention of Acanthamoeba keratitis by inducing immunity before infection occurs. Immunization thus may eventually become the best approach for reduction of the incidence of amebic infection in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145728     DOI: 10.1086/341487

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

1.  Effect of combined chlorhexidine gluconate and neosporin on experimental keratitis with two pathogenic strains of Acanthamoeba.

Authors:  Zubeyde Akin Polat; Ayse Vural
Journal:  Parasitol Res       Date:  2011-12-09       Impact factor: 2.289

2.  In vitro amoebicidal activities of Satureja cuneifolia and Melissa officinalis on Acanthamoeba castellanii cysts and trophozoites.

Authors:  E Malatyali; B Tepe; S Degerli; S Berk
Journal:  Parasitol Res       Date:  2011-12-09       Impact factor: 2.289

3.  In vitro amoebicidal activity of ethanol extracts of Arachis hypogaea L., Curcuma longa L. and Pancratium maritimum L. on Acanthamoeba castellanii cysts.

Authors:  Nagwa Mostafa El-Sayed; Khadiga Ahmed Ismail; Sabah Abd-El-Ghany Ahmed; Mona Hafez Hetta
Journal:  Parasitol Res       Date:  2011-12-07       Impact factor: 2.289

4.  Biochemical characterization and functional studies of Acanthamoeba mannose-binding protein.

Authors:  Marco Garate; Ibis Cubillos; Jeffrey Marchant; Noorjahan Panjwani
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Oral immunization with Acanthamoeba castellanii mannose-binding protein ameliorates amoebic keratitis.

Authors:  M Garate; H Alizadeh; S Neelam; J Y Niederkorn; N Panjwani
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

6.  Acanthamoeba species Keratitis in a Soft Contact Lens Wearer Molecularly Linked to Well Water.

Authors:  Samira Mubareka; Michelle Alfa; Godfrey K Harding; Gregory Booton; Marilyn Ekins; Paul Vancaeseele
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

7.  Tigecycline inhibits proliferation of Acanthamoeba castellanii.

Authors:  Bijay Kumar Jha; Incheol Seo; Hyun-Hee Kong; Seong-Il Suh; Min-Ho Suh; Won-Ki Baek
Journal:  Parasitol Res       Date:  2015-01-07       Impact factor: 2.289

8.  In Vitro activity of Manuka Honey and polyhexamethylene biguanide on filamentous fungi and toxicity to human cell lines.

Authors:  Joseph M Yabes; Brian K White; Clinton K Murray; Carlos J Sanchez; Katrin Mende; Miriam L Beckius; Wendy C Zera; Joseph C Wenke; Kevin S Akers
Journal:  Med Mycol       Date:  2017-04-01       Impact factor: 4.076

9.  Cytotoxic effect of acriflavine against clinical isolates of Acanthamoeba spp.

Authors:  Zubeyda Akin Polat; Gulderen Karakus
Journal:  Parasitol Res       Date:  2012-10-10       Impact factor: 2.289

10.  Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.

Authors:  Zubeyde Akın Polat; Andreas Obwaller; Ayse Vural; Julia Walochnik
Journal:  Parasitol Res       Date:  2011-07-07       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.